[Fundamental and clinical studies on cefpimizole in the field of obstetrics and gynecology].
Fundamental and clinical studies on cefpimizole (AC-1370), a new cephem antibiotic, were performed and the following results were obtained: Concentration of AC-1370 was examined in serum, internal genital organs and retroperitoneal fluid after single intravenous administration of 2.0 g dose. The venous serum level of AC-1370 was 243 micrograms/ml at 30 minutes after the administration. The sufficient transfer of AC-1370 to internal genital organs and retroperitoneal fluid was recognized. In clinical trial, AC-1370 was given to 10 cases with obstetrical and gynecological infections. The efficacy was evaluated as good in 8 cases and poor in 2 cases. No side effects were observed in any of the cases treated with AC-1370.
D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D002511:Cephalosporins / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D004341:Drug Evaluation; D005122:Exudates and Transudates / Q000378:metabolism; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy*; D005836:Genitalia, Female / Q000378:metabolism; D006801:Humans; D008875:Middle Aged; D010388:Pelvis; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy
D002511:Cephalosporins; C038845:cefpimizole